Cargando…
Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results
Patients with overt clinical atherosclerosis (ATS) or with previous peripheral vascular events have a high risk of ischaemic complications. A careful control of cardiovascular (CV) risk factors has been shown to improve prognosis, likely driven by a decrease progression of ATS. Prevention of occlusi...
Autores principales: | Savonitto, Stefano, Pelizzoli, Silvia, Selva, Antonia Maria |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7270902/ https://www.ncbi.nlm.nih.gov/pubmed/32523458 http://dx.doi.org/10.1093/eurheartj/suaa079 |
Ejemplares similares
-
Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial
por: Ramacciotti, Eduardo, et al.
Publicado: (2022) -
Chronic ischaemic heart disease and rivaroxaban: which patients derive the greatest benefit?
por: Bolognese, Leonardo, et al.
Publicado: (2020) -
Use of direct oral anticoagulant in ischaemic heart disease: the COMPASS study
por: Ferri, Luca A, et al.
Publicado: (2019) -
Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease
por: Cowie, Martin R, et al.
Publicado: (2020) -
Revascularisation for Ischaemic Cardiomyopathy
por: Li Kam Wa, Matthew E, et al.
Publicado: (2023)